# Nuclide record hcc (indication). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/indications/hcc/>
  a schema:MedicalCondition ;
  nuclide:kind "indication" ;
  schema:identifier "hcc" ;
  schema:name "Hepatocellular carcinoma"@en ;
  schema:alternateName "Liver Cancer"@en ;
  schema:description "Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."@en ;
  schema:url <https://nuclide.cc/indications/hcc/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Hepatocellular_carcinoma> ;
  owl:sameAs <http://www.wikidata.org/entity/Q1148337> ;
  schema:citation <https://en.wikipedia.org/wiki/Hepatocellular_carcinoma> ;
  nuclide:tag "gi", "spike" ;
  nuclide:technologies <https://nuclide.cc/technologies/radioembolisation-tare/> ;
  nuclide:targets <https://nuclide.cc/targets/gpc3/>, <https://nuclide.cc/targets/fap/> ;
  nuclide:companies <https://nuclide.cc/companies/astrazeneca/>, <https://nuclide.cc/companies/bms/>, <https://nuclide.cc/companies/merck/>, <https://nuclide.cc/companies/bayer/>, <https://nuclide.cc/companies/eli-lilly/>, <https://nuclide.cc/companies/sirtex/>, <https://nuclide.cc/companies/boston-scientific/> ;
  nuclide:institutions <https://nuclide.cc/institutions/mayo-clinic/>, <https://nuclide.cc/institutions/mskcc/> ;
  nuclide:terms <https://nuclide.cc/terms/dosimetry/> ;
  nuclide:pipeline <https://nuclide.cc/technologies/fapi-pet/>, <https://nuclide.cc/technologies/radioembolisation-tare/>, <https://nuclide.cc/targets/gpc3/>, <https://nuclide.cc/drugs/cabozantinib/> ;
  nuclide:standardOfCare <https://nuclide.cc/technologies/radioligand-therapy/>, <https://nuclide.cc/drugs/durvalumab/>, <https://nuclide.cc/technologies/radioembolisation-tare/>, <https://nuclide.cc/technologies/radioembolisation-tare/>, <https://nuclide.cc/drugs/durvalumab/>, <https://nuclide.cc/drugs/sorafenib/>, <https://nuclide.cc/drugs/cabozantinib/>, <https://nuclide.cc/technologies/radioembolisation-tare/> .